New drugs against Alzheimer’s disease

Alzheimer's, one of the most challenging neurodegenerative diseases of our time, affects millions of people worldwide and places an immense burden on both sufferers and their families. With an ageing population, understanding and effectively treating this disease is becoming increasingly important. This book provides a comprehensive overview of the various facets of Alzheimer's - from the different forms of the disease, its causes and its curability, to the latest advances in research and promising new drugs. Particularly noteworthy is the detailed presentation of new drugs such as aducanumab, lecanemab, donanemab, semaglutide, buntanetap and GV-971. Each drug is comprehensively analysed, from mode of action and availability to clinical trials and results, side effects and regulatory approvals. In addition, the book sheds light on the revolutionary possibilities of gene editing technologies such as CRISPR-Cas9 and their potential contribution to the treatment of Alzheimer's disease. This book is aimed at anyone interested in the latest developments in Alzheimer's research and the future of treatment options.